NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL... January 4, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
Update on CALAVI Phase II trials for Acalabrutinib in Patients Hospitalized with Respiratory Symptoms of COVID-19 There has been much excitement about the possibility that BTK inhibitors such as ibrutinib or acalabrutinib might improve outcomes in... January 4, 2021C19 - Updates, Clinical, COVID-19By Brad Hedrick
CLL Society’s Official Statement Concerning SARS-CoV-2 Vaccine in CLL Patients 1/04/2021 CLL Society’s Official Statement Concerning SARS-CoV-2 Vaccine in CLL patients 1/04/2021 We have heard your questions! Should I get the vaccine? Is... January 4, 2021COVID-19, Official Statements and Press ReleasesBy Brad Hedrick
Do I need a Pulse Oximeter? Do I need a Pulse Oximeter? Along with a thermometer, a pulse oximeter is perhaps the most useful home diagnostic medical... December 4, 2020C19 - Updates, COVID-19, Official Statements and Press ReleasesBy Brad Hedrick
Dr. Koffman on COVID-19 Vaccines CLL Meets COVID Vaccines. Dr. Koffman shares what we know, what we don't know and next steps here.... November 30, 2020C19 - Updates, COVID-19, Official Statements and Press ReleasesBy Brad Hedrick
Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients... November 25, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
Dr. Susan O’Brien named “Giant of Cancer Care”! Dr. Susan O'Brien named "Giant of Cancer Care"! Dr. Susan O’Brien's decades of research and clinical care have dramatically improved the... November 23, 2020NewsBy Brad Hedrick
Case Study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer (chronic lymphocytic leukemia or CLL) patient. This single case has created a buzz in the chronic lymphocytic leukemia community because the patient had CLL. Here are some... November 13, 2020C19 - Updates, COVID-19, NewsBy Brad Hedrick
Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia Calquence (acalabrutinib) is a 2nd generation BTK inhibitor with a different side effect profile than ibrutinib. It is already approved... November 13, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
NICE okays chemotherapy-free combination venetoclax plus obinutuzumab for all front-line patients with chronic lymphocytic leukaemia (CLL) NICE gives green light for chemotherapy-free combination of venetoclax plus obinutuzumab for all front-line patients with CLL ... November 13, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
